May 24, 2017. The FDA should be sure that new treatments provide a real benefit to patients before they are approved. We recommend that the FDA not approve neratinib for breast cancer unless a clear benefit can be replicated, or a benefit for overall survival is demonstrated.
May 9, 2017. Good afternoon. I appreciate the opportunity to address this distinguished panel and our FDA participants. I’m Jack Mitchell, director of government relations for the National Center for Health Research (NCHR). We conduct research, use research data to inform public policy, and advocate for safe and effective medical products. NCHR accepts no pharmaceutical or medical device industry money, and therefore I have no conflicts to report.
National Center for Health Research’s Comments on the U.S. Preventive Services Task Force’s Draft Recommendation Statement on Prostate Cancer Screening Thank you for the opportunity to express our views on the draft recommendations for prostate cancer screening. The National Center for Health Research is a nonprofit think tank that conducts, analyzes, and scrutinizes research, policies, […]
April 12, 2017. Based on its previous review, the USPSTF recommended risk assessment, genetic testing, and counseling for women with a family history of clinically important mutations in BRCA1 or BRCA2 genes.
April 19, 2017. In their previous recommendation, USPSTF found that treatment with tamoxifen or raloxifene was beneficial for a subpopulation of women at increased risk. However, these treatments only slightly reduced the occurrence of invasive breast cancer in these women and came with serious risks